TEL AVIV, Israel, March 17, 2023 /PRNewswire/ --
Isaac Brownell, M.D, Ph.D., Senior Investigator, Chief, Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin DiseasesArthritis and Musculoskeletal and Skin Diseases, stated "The real-world data, collected from more than 5,000 patients, as published in the IQVIA database and analyzed by Trinity, confirms that a meaningful percentage of cancer patients treated with epidermal growth factor receptor (EGFR) inhibitorsepidermal growth factor receptor (EGFR) inhibitors develop a serious/severe rash. While such patients are commonly treated prophylactically with antibiotics, there is insufficient evidence to support its practice, leading to a significant unmet medical need." "Preliminary results from Lutris' phase 2 trial of lead compound, LUT014, a topically applied, novel B-Raf inhibitor being studied in metastatic colorectal cancer patients (mCRC) treated with EGFR inhibitor therapy who have developed dose-limiting acneiform lesions, have been highly promising. As a result, we believe that LUT014 has the potential to become an important therapeutic for EGFRi induced skin toxicity and can have a tremendous impact for patients who currently have no other effective treatment options," added Noa Shelach, Ph.D., Chief Executive Officer of Lutris Pharma. Poster details are as follows:
Title: Real-world analysis of skin toxicity from EGFR inhibitorsEGFR inhibitors: an unmet challenge Authors: Austin J. Jabbour, M.D., Noreen Mohsin, Ali Khan, Myra Zahee, Noa Shelach, Ph.D., Benjamin W. Corn, M.D., Isaac Brownell, M.D., Ph.D.
The analysis showed that the use of prophylactic antibiotics delayed, but did not prevent, EGFRi-associated rash. Global sales and claims data reflect large populations of EGFRi treated cancer patients, however real-world data from U.S. cancer patients using EGFRI's detects skin rash in 34%. However, clinical trial data and the FDA label suggests the rash occurs at a notably higher frequency than was measured in this study, suggesting under-reporting of rash diagnosis. The poster will be available after the event on the "Events and Presentations" section of Lutris' website at: https://www.lutris-pharma.com/events-and-presentations/